Reports Q3 revenue $42.05M vs. $48.7M last year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKBA:
- Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- AKBA Earnings this Week: How Will it Perform?
- Akebia announces FDA accepted resubmission of NDA for vadadustat
- Akebia resubmits New Drug Application to the FDA for vadadustat
- Akebia lowers 2023 Auryxia net product revenue guidance